Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 4/20 | 0.42 |
| ▸ | SCN2B | O60939 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN4A | P35499 | 1/20 | 0.42 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19083703 | 0.87 | SCN9A (0.47) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL19083968 | 0.84 | SCN9A (0.49) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL21075324 | 0.84 | SCN9A (0.49) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL17428740 | 0.83 | SCN9A (0.52) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL17428931 | 0.83 | SCN9A (0.52) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL21075105 | 0.83 | SCN9A (0.52) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL20498883 | 0.83 | SCN9A (0.61) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL17428667 | 0.83 | SCN9A (0.61) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL21075447 | 0.82 | SCN9A (0.48) | SCN9ASCN5ASCN7ASCN2BSCN1A | |
| SCHEMBL21075463 | 0.82 | SCN9A (0.48) | SCN9ASCN5ASCN7ASCN2BSCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885SCN5A 1598/4885SCN7A 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.